Editorial Comment: Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer

Int Braz J Urol. 2021 Jan-Feb;47(1):200-201. doi: 10.1590/S1677-5538.IBJU.2021.01.08.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Androgen Antagonists / therapeutic use
  • Androstenes*
  • Hormones
  • Humans
  • Male
  • Prostatic Neoplasms* / drug therapy

Substances

  • Androgen Antagonists
  • Androstenes
  • Hormones
  • abiraterone